Human Genome Sciences Inc.

H. Thomas Watkins joined HGS as Chief Executive Officer and a Director in December 2004, and was also named President in December 2005. Mr. Watkins came to HGS with nearly twenty years of experience at Abbott Laboratories and its affiliates in the U.S. and Asia. He joined Abbott in 1985 and held various executive positions in the Pharmaceutical Products Division, Diagnostics Division and HealthSystems Division prior to serving as President of TAP Pharmaceutical Products, Inc., from 1998 to 2004. Mr. Watkins began his career in 1974 with Arthur Andersen & Co., and was a management consultant with McKinsey and Company, Inc., from 1979 to 1985. Mr. Watkins holds a bachelor’s degree from the College of William and Mary, and a master’s degree in business administration from the University of Chicago Graduate School of Business. He is a member of the Board of Directors of Vanda Pharmaceuticals, Inc., the Biotechnology Industry Organization (BIO), the U.S. Chamber of Commerce, and the National Symphony Orchestra. He is a Trustee of The College of William and Mary Foundation and a member of the Board of Trustees of The Mason School of Business of The College of William and Mary. Mr. Watkins currently serves as Chair of the Life Sciences Advisory Board of the State of Maryland, and is a member of the Board of Visitors of the University of Maryland Biotechnology Institute.

Barry A. Labinger joined HGS in August 2005 as Executive Vice President and Chief Commercial Officer. Mr. Labinger has more than 15 years of experience in the biopharmaceutical industry, including leadership of launches and marketing of a number of successful products in a variety of therapeutic areas. Mr. Labinger was most recently with 3M Pharmaceuticals, where he served as Division Vice President. 3M Pharmaceuticals is a global division of 3M Company with marketed products in dermatology, women’s health, and cardiac therapy, along with a pipeline of immune response modifiers for the treatment of viral infections and cancers. From 2000 to 2002, Mr. Labinger was Senior Vice President and General Manager, Commercial Operations, at Immunex Corporation where he led both the Enbrel and Specialty Therapeutics franchise teams and had direct responsibility for the sales and marketing organizations. Mr. Labinger also served as Senior Director of Diabetes Marketing and Director of Glucophage Marketing at Bristol-Myers Squibb. Mr. Labinger began his pharmaceutical career at Abbott Laboratories, where he was involved in the commercialization of products for gastrointestinal and infectious diseases. Mr. Labinger earned a Master of Business Administration degree from the J.L. Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Arts in economics from Northwestern University.

Mr. Barabe joined HGS in July 2006. He has held a broad range of financial and strategic roles in the life sciences and healthcare industries. From September 2005 to June 2006, Mr. Barabe was Managing Director of the U.K. for Regent Medical Ltd., a U.K.-based privately owned surgical supply company, having been its Chief Financial Officer from 2004 to September 2005. Prior to joining Regent, Mr. Barabe was with Novartis AG from 1982-2004 in a succession of senior executive positions in finance, general management, and strategic planning, including Chief Financial Officer of the Sandoz Generics Business Unit (Vienna, Austria), President of the CIBA Vision Corporation Specialty Lens Business Franchise, Group Vice President and Chief Financial Officer of CIBA Vision Corporation, and Director of Corporate Finance, Ciba-Geigy Corporation (subsequently acquired by Novartis AG). Mr. Barabe received his MBA in Finance from the University of Chicago and his BBA in Finance from the University of Massachusetts. He is a member of the Board of Directors of ArQule, Inc.

David C. Stump joined the Company in November 1999 as Senior Vice President, Drug Development. In December 2003, he was promoted to Executive Vice President. Dr. Stump came to HGS from Genentech, Inc., where he was Vice President, Clinical Research, since 1995. In 1996 he was named a Genentech Fellow, only the second in Genentech’s history. Dr. Stump also served as a member of the Genentech Product Development Committee and chaired the Clinical Review Committee. While he was closely involved with overall clinical development efforts during his last five years at Genentech, Dr. Stump was most widely recognized for a decade of leadership of the company’s thrombolytic therapy drug development program, which accomplished multiple successful clinical trials and drug approvals for patients with acute myocardial infarction and acute ischemic stroke. Dr. Stump joined Genentech in 1989 from the University of Vermont where he was Associate Professor of Medicine and Biochemistry. He holds an A.B. from Earlham College and an M.D. from Indiana University. Dr. Stump received residency and fellowship training in internal medicine, hematology and oncology at the University of Iowa, where he also received advanced research training in biochemistry. In addition, he completed specialized training in hemostasis research as a visiting investigator at the University of Leuven, Belgium. Dr. Stump is certified by the American Board of Medicine, including its Medical Oncology and Hematology Subspecialty Boards. He holds membership in a variety of professional organizations and is an elected Fellow of the American College of Physicians and of the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. Dr. Stump is a member of the Board of Trustees of Adventist HealthCare and the Board of Directors of Sunesis Pharmaceuticals Inc.

James H. Davis joined HGS as Senior Vice President, General Counsel and Secretary in May 1997. In December 2003, Dr. Davis was promoted to Executive Vice President. Prior to joining HGS, Dr. Davis was with the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P., where his practice focused on providing an integrated analysis of legal issues affecting the commercialization of new technologies, including intellectual property rights, regulatory compliance and licensing. Prior to joining Finnegan, Henderson in 1995, Dr. Davis served as General Counsel, Vice President of Research and Development, and a Director of Crop Genetics International Corporation, which he had joined in 1988 as General Counsel and Vice President of Development and Regulatory Affairs. Earlier in his career, Dr. Davis was a Partner with Weil, Gotshal & Manges, which he joined in 1986, with a practice principally concentrated on counseling and litigation relating to environmental, health, food, drug and cosmetic issues. From 1983 to 1985, he served with the U.S. Environmental Protection Agency. Dr. Davis holds a doctorate degree in Organic and Theoretical Chemistry from the California Institute of Technology, a law degree from the University of Virginia, and his Bachelor of Science and Master of Science in Chemistry degrees from Yale University. Dr. Davis serves on the Board of Directors of the Leukemia and Lymphoma Society.

Curran M. Simpson joined HGS in March 2003 as Vice President, Manufacturing Operations. He was promoted to Senior Vice President, Operations, in December 2005. Prior to joining HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen's North Carolina facility. In this role, he led the technology transfer, start-up and validation activities for Biogen's large-scale manufacturing facility, and completed a successful pre-approval inspection (PAI) resulting in commercialization of Amevive. Previous to his position with Biogen, Mr. Simpson held process development and manufacturing positions with several biotechnology companies, including Genencor, Genentech, Novo-Nordisk (U.S. and Europe) and Covance. Mr. Simpson has been involved in the scale-up and manufacturing operations for a number of commercial products, including Pulmozyme, TNKase, Herceptin and Retavase. Mr. Simpson earned his M.S. degree in Surface and Colloid Science (Physical Chemistry) from Clarkson University, and his B.S. degree in Chemical Engineering/Chemistry from the Clarkson College of Technology

Sally D. Bolmer joined HGS in February 2000 as Vice President, Regulatory Affairs. In December 2002, Dr. Bolmer was promoted to Senior Vice President. She joined HGS from Centocor, Inc., where she held several positions, most recently Executive Director, Worldwide Regulatory Affairs. In that position, Dr. Bolmer had overall responsibility for developing and implementing Centocor's worldwide regulatory strategies for cardiovascular products. These responsibilities included overseeing the preclinical, clinical and manufacturing submissions for investigational new drugs and product licensing applications for biological and gene therapy products as well as preparation and maintenance of submissions for single- and multi-product facilities. Dr. Bolmer joined Centocor from Mount Sinai Medical Center, New York City, where she was Assistant Research Professor of Pathology. Previously, she was a Post-Doctoral Associate at Massachusetts Institute of Technology. Dr. Bolmer earned a Ph.D., in Biological Chemistry from Pennsylvania State University, and an Sc.B., in Biochemistry from Brown University. Dr. Bolmer is a member of the Regulatory Affairs Professional Society.

Susan Bateson joined HGS as Vice President, Human Resources in January 1997. In December 2000, Ms. Bateson was promoted to Senior Vice President. Prior to joining HGS, Ms. Bateson served as Director of Human Resources and Administration at the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. in Washington, D.C. Prior to joining Finnegan, Henderson in 1994, Ms. Bateson was employed by J.P. Morgan & Co. Incorporated, where she served in various leadership roles within Human Resources in the company's New York, Delaware, and London offices. Earlier in her career, Ms. Bateson held various human resources positions with Citicorp and was a financial analyst at Bankers Trust. Ms. Bateson earned her MBA in International Management from New York University's Stern School of Business and her B.A. cum laude in Economics from Mount Holyoke College. Ms. Bateson currently serves on the Board of Trustees of Mount Holyoke College, where she chairs the Audit Committee, and on the Board of Advisors of The Universities at Shady Grove, Rockville, Maryland.

Ann L. Wang joined HGS as Director of Clinical Operations in December 2000. She was promoted to Vice President, Clinical Operations in December 2003. Prior to HGS, Ms. Wang was Director of Clinical Operations for Pharmaceutical Research Associates International (PRA), a contract research organization where she was responsible for directing delivery of clinical trials services to PRA clients. From 1988-1998, Ms. Wang advanced through a series of clinical operations positions of increasing responsibility at Centocor, Inc., ultimately serving as Associate Director, Clinical Operations and Administration. While at Centocor, she led implementation of the program leading to worldwide approval of the recombinant antiplatelet drug, ReoPro. Ms. Wang began her career in as a bench scientist, first at the Lombardi Cancer Research Center of Georgetown University and then at SmithKline & French, where she was responsible for establishing a Molecular Oncology laboratory. Ms. Wang earned her B.A. in Organismal Biology at The Johns Hopkins University and did postgraduate work at Georgetown University in physiology.

Daniel Odenheimer joined the HGS drug development team in 1998. In 2003, he was promoted to Vice President, Clinical Research - General Medicine. Dr. Odenheimer's responsibilities include developing clinical plans for new products, designing clinical trials, and recruiting and monitoring clinical trial investigators for clinical trials. Prior to joining HGS, Dr. Odenheimer worked at British Biotech Inc., where he was Director, U.S. Clinical Research. Among his responsibilities were directing the U.S. clinical development of marimastat in lung cancer and non-oncology indications. Previously, Dr. Odenheimer worked at Boehringer Mannheim Corporation's Therapeutics division. During his eight years there, he advanced through a series of positions, including Director, Department of Clinical Research. Dr. Odenheimer earned a Ph.D. in Epidemiology and an M.S. degree in Biostatistics at the University of Michigan. He earned an M.S. in Epidemiology and a B.S. in Genetics from the University of California, Berkeley.

Jerry Parrott joined HGS in July 2001 as Vice President, Corporate Communications and Public Policy. As Principal of Policy Advocates, Inc., from 1995-2001, Mr. Parrott’s clients included HGS, Bristol-Myers Squibb, Ciba-Geigy, Diversa, Genentech, HealthCare Ventures, Hoffmann-La Roche, Western Digital, Wyeth and other companies. He previously held senior policy and corporate communications management positions with Bristol-Myers Squibb Company (1979-1995), American Hospital Supply Corporation (1976-1979), and Walgreen Company (1973-1976). Mr. Parrott helped launch several important therapeutic products, including: Zenapax, the first genetically engineered drug to reduce risk of organ rejection; VIDEX, the second anti-AIDS drug; Taxol, the breakthrough cancer drug; Nuprin, the first nonprescription ibuprofen; and Comtrex, the nonprescription cough-cold medicine. He received his B.A. from the University of South Florida and attended graduate school as a University Fellow at Northwestern University. Mr. Parrott is Chair of the Board of Directors of Maryland Health Care Product Development Corporation, and a member of the Executive Committee and Board of Directors of MdBio and the Technology Council of Maryland

Joseph (Joe) A. Morin joined HGS in 1997 as Senior Director of Capital Projects and Facilities. He was promoted to Vice President of Capital Projects, Facilities, and Engineering in October 2002. Prior to joining HGS, Mr. Morin served in a succession of project engineering roles of increasing responsibility at Celltech Biologics, now Lonza Biologics. While at Celltech, Mr. Morin was responsible for engineering, procurement, and construction management, from initial concept through to installation qualification, for large and small capital projects, including the initial construction and ultimate qualification of the Company’s biologics manufacturing facility. Mr. Morin began his career in construction and then as an engineer with Appledore Engineering, Inc., where he worked on large civil, structural and marine projects. Mr. Morin received his bachelor of science in industrial technology at the University System of New Hampshire’s Keene State College.

Michele M. Wales joined the HGS Intellectual Property department in 1998, and was promoted to Vice President, Intellectual Property, in 2007. Prior to HGS, Dr. Wales was with the intellectual property law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., where she began her legal career in 1995. Dr. Wales earned her Ph.D. in human genetics and molecular biology from The Johns Hopkins Medical School, where she did post-doctoral work in the Department of Oncology. She earned her J.D. from George Washington University National Law Center, and her B.S. cum laude in molecular and cellular biology from the University of Connecticut. While at Johns Hopkins, Dr. Wales co-discovered and characterized the novel tumor suppressor gene, HIC-1, which is associated with the development of a number of cancers and for which patents have been granted.

Randy Maddux joined HGS in March 2004 as Vice President of Quality. He was named Vice President, Manufacturing Operations, in December 2005. Prior to joining HGS, Mr. Maddux was Director of Quality at the Research Triangle Park, NC campus of Biogen Idec. In his eight years at Biogen, he established Biogen’s quality control function, including the development of systems and monitoring programs. He also led preparation activities for the commercial licensing of Biogen's Large Scale Manufacturing facility. Prior to his position with Biogen, Mr. Maddux served in a number of roles of increasing responsibility at Glaxo Wellcome at Research Triangle Park, including Supervisor of Clinical QA/QC, Group Leader of Methods Development and Automation, and Assistant Director of R&D Operations. Mr. Maddux earned a BS in Chemistry from East Carolina University and an MBA from Duke University, Fuqua School of Business.

Sarah Thomas joined HGS in 2003 as Director of Quality Assurance. She was promoted to Vice President, Quality in 2007. In her current position she is responsible for the Quality Assurance and Quality Control functions at HGS. Prior to joining HGS, Ms. Thomas held positions in Quality Assurance with increasing levels of responsibility at several biotechnology and pharmaceutical firms including Cell Genesys, Alza Corporation, Sequus Pharmaceuticals, Syntex and Adria-SP. In her career she has worked with products at various stages of clinical and commercial development, guiding Quality programs through the transition from clinical to commercial manufacturing, including Pre-Approval Inspection and commercial launch. Ms. Thomas earned an M.B.A. from George Washington University and a B.S. in Chemistry from Butler University.

Thomas M. Spitznagel joined HGS in March 1998 as Group Leader, Formulation. Dr. Spitznagel has moved through a number of positions of increasing responsibility, including oversight of Analytical Development, Drug Delivery, Purification Sciences, Fermentation and Cell Culture Sciences, and Global Project Management. He was promoted to Vice President, BioPharmaceutical Development in May 2008. Prior to joining HGS, Dr. Spitznagel was a Senior Scientist at Nabi Biopharmaceuticals from 1996-1998, and a Staff Engineer at Genetics Institute from 1992-1996. During his tenure at Nabi, Dr. Spitznagel was responsible for scale-up and development of the purification process for polysaccharide-protein conjugate vaccines. During his tenure at Genetics Institute, Dr. Spitznagel was responsible for formulation and delivery system development for rhBMP-2, as well as finished product process development. Dr. Spitznagel earned his BS in Chemical Engineering at M.I.T, and his Ph.D. in Chemical Engineering at the University of California, Berkeley.

William W. Freimuth joined HGS in August 2000 as Director of Clinical Research, Immunology and Infectious Diseases. In December 2003, he was promoted to Vice President, Clinical Research – Immunology, Rheumatology and Infectious Diseases. Before coming to HGS, Dr. Freimuth was with Pharmacia & Upjohn, most recently serving as Therapeutic Area Clinical Director – Antiviral. He joined the Phase 1/2 clinical research unit of Upjohn in 1992 and during his tenure at Pharmacia & Upjohn held a number of clinical research management positions, including responsibility for worldwide clinical development of four antiviral agents. From 1986-1992, Dr. Freimuth completed his Residency in Internal Medicine and his Rheumatology fellowship training at the University of Michigan Medical Center in Ann Arbor. Dr. Freimuth earned his M.D. from the State University of New York at Buffalo (SUNYAB) School of Medicine, where he subsequently did postdoctoral research in immunology and immunogenetics. Dr. Freimuth received his Ph.D. in Immunology from Michigan State University, and his B.S. in microbiology from the University of Michigan.

Mr. Lawlor has over fifteen years operating experience in the biotechnology industry in finance, business development, mergers and acquisitions, and general management. Before joining HealthCare Ventures, he was Chief Operating Officer of LeukoSite, Inc. Prior to joining LeukoSite, Mr. Lawlor was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology. He was previously Chief Financial Officer and Vice President of Business Development of BioSurface Technology. He received a Master's Degree in Management from Yale University. He joined HCV in 2000.

Mr. Ha-Ngoc is President and CEO of AVEO Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the discovery and development of novel cancer therapeutics. From 1999 to 2002, he was co-founder, President and CEO of deNovis, Inc., an enterprise-scale software development company for the automation of healthcare administrative functions. From 1998 to 1999, Mr. Ha-Ngoc was Corporate Vice President of Strategic Development for Wyeth, following Wyeth's acquisition of Genetics Institute, where Mr. Ha-Ngoc served as Executive Vice President with responsibility for Corporate Development, Commercial Operations, European and Japanese Operations. Prior to joining Genetics Institute in 1984, Mr. Ha-Ngoc held various marketing and business positions at Baxter Healthcare, Inc. He received his MBA degree from INSEAD and his Master's degree in pharmacy from the University of Paris, France. Mr. Ha-Ngoc serves on the Board of Directors of ArQule, Inc., Human Genome Sciences, Inc., and on the Boards of a number of academic and nonprofit organizations, including the Harvard School of Dental Medicine, the Tufts School of Medicine, the Belmont Hill School, the Boston Philharmonic Orchestra, and the International Institute of Boston.

Argeris (Jerry) N. Karabelas is Chairman of the Board and a member of the Compensation Committee. He has been a partner of Care Capital LLC since 2001 and was the Founder and Chairman of Novartis BioVenture Fund from 2000 to 2001. Dr. Karabelas was also the Head of Healthcare and CEO of Worldwide Pharmaceuticals at Novartis, AG from 1998 to 2000; Executive Vice President, Pharmaceuticals, at SmithKline Beecham from 1997 to 1998; President, North American Pharmaceuticals, at SmithKline Beecham from 1993 to 1997; and Vice President, U.S. Marketing, at SmithKline Beecham from 1990 to 1993. Dr. Karabelas is a Visiting Committee Member of MIT Health Studies & Technology; Director of SkyePharma PLC; Chairman of Nitromed, Inc.; Director of Cyreniac Pharmaceutical; Director of Minster Pharmaceuticals plc; Director of Renovo PLC; Chairman of Vanda Pharmaceuticals Inc.; and Director of Inotek, Inc.

David P. Southwell, age 48, has served as our director since January 1997 and as Chairman of our board of directors since March 2005. Since September 2008, Mr. Southwell has served as Chief Financial Officer of BioNevia Pharmaceuticals, Inc. He served as Executive Vice President and Chief Financial Officer of Sepracor Inc. from October 1995 to May 2008, and served as Senior Vice President and Chief Financial Officer of Sepracor Inc. from July 1994 to October 1995. From August 1988 until July 1994, Mr. Southwell was associated with Lehman Brothers Inc., a securities firm, in various positions within the investment banking division, including in the position of Vice President. Mr. Southwell is also a director of Human Genome Sciences Inc. and Panel Intelligence LLC, PTC Therapeutics, Inc., and serves on the Advisory Board of the Tuck School of Business at Dartmouth College.

Dr. Jürgen Drews is a member of the Nominating and Governance Committee. Dr. Drews served as Chairman and Partner of International Biomedicine Management Partners, Basel, Switzerland, from 1997 to 2001. He was Managing Partner of Bear Stearns Health Innoventures from 2001 to 2004 and a member of the Executive Committee of the Roche Group, Hoffman-La Roche, Inc. from 1986 until his retirement in 1998. Dr. Drews also served as President of Global Research for the Roche Group from 1996 to 1998. He was President of International Research and Development at the Roche Group from 1991 to 1996. Before joining Roche in 1985, Dr. Drews was Head of International Pharmaceutical Research and Development of Sandoz, Ltd., Basel, Switzerland. Dr. Drews serves as Chairman of the Board of Directors of GPC-biotech AG and is a Director of MorphoSys GmbH, both in Munich, Germany.

Managing Partner, Bear Stearns Health Innoventures Management, L.L.C. Jurgen Drews joined Bear Stearns from IBMP, a $70 million biotech venture fund, where he was co-founder and Chairman of the Board. From 1986 to 1997, Dr. Drews was President of Global Research and Development and a member of the Executive Committee at Hoffmann-La Roche. From 1970 to 1978 he was Head of Microbiology at the Sandoz Research Institute in Vienna. Between 1979 and 1982 he was Managing Director of this institute. He and Dr. Ryser co-authored several watershed articles on productivity in the pharmaceutical industry described on the following page. Dr. Drews is the author of the 1999 book "In Quest of Tomorrow's Medicines." He serves on the board of several leading biotech companies and is past President of the Brussels-based Senior Advisory Group on Biotechnology (later named EuropaBio). Dr. Drews is a professor of Internal Medicine at the University of Heidelberg, Germany, and a professor of Molecular Genetics at The University of Medicine and Dentistry, New Brunswick, NJ. Between 1998 and 2000 he also consulted for Orbimed Advisors LLC, a New York company managing health care funds. Dr. Drews received his M.D. degree from the Free University of Berlin and did postdoctoral work at the University of Frankfurt and Yale University. BSHI portfolio: Dr. Drews currently is the chairman of the supervisory board of Tegenero Immuno Therapeutics AG.

Richard is currently the Nunn Prize Fellow at the Center for Strategic and International Studies in Washington, DC, a senior fellow at the CNA Corporation, and a consultant to the Department of Defense. Richard served as the 71st Secretary of the Navy from 1998 to 2001. He was the Undersecretary of the Navy from 1993 to 1997. He is currently a director at National Semiconductor Corporation, Human Genome Sciences Corporation, and Saffron Hill Ventures. He also serves as Chairman of the Board of the Center for Strategic and Budgetary Assessments, and a member of the Board of Directors of Public Agenda and the Partnership for Public Service. He holds a BA from Reed College, a JD from Yale Law, and a PhD from Oxford, where he was a Rhodes Scholar. He has three times received the Department of Defense's highest award for civilians, the Defense Distinguished Public Service Award

Richard Danzig is a member of the Audit Committee. He serves as a consultant to the U.S. government on biological terrorism. He is a Nunn Prize Fellow at the Center for Strategic and International Studies and Senior Fellow at the Center for Naval Analyses. Mr. Danzig is also a member of the U.S. Military Southern Command Advisory Board. He serves on the boards of directors of National Semiconductor Corporation and Saffron Hill Ventures, the Center for a New American Security and the Partnership for Public Service. He served as Secretary of the Navy from 1998 to 2001 and as Under Secretary of the Navy from 1993 to 1997. He was a Traveling Fellow of the Center for International Political Economy and an Adjunct Professor at Syracuse University's Maxwell School of Citizenship & Public Affairs between 1997 and 1998. He was a partner in the law firm of Latham and Watkins from 1981 to 1993.

Robert D. Hormats is Vice Chairman of Goldman Sachs (International) and Managing Director of Goldman Sachs & Co. Mr. Hormats was Assistant Secretary of State for economic and business affairs from 1981 to 1982. From 1969 to 1977 he served on the National Security Council and, as Senior Economic Advisor, he counseled Dr. Henry Kissinger, General Brent Scowcroft and Dr. Zbigniew Brzezinski. Mr. Hormats was a recipient of the French Legion of Honor in 1982 and the Arthur Fleming Award in 1974. He is a member of the board of the Council on Foreign Relations, Englehard Hanovia, Inc., and Human Genome Sciences, Inc.